Core Viewpoint - The Schall Law Firm is investigating Exelixis, Inc. for potential violations of securities laws related to misleading statements and undisclosed information affecting investors [1][2]. Group 1: Investigation Details - The investigation centers on whether Exelixis issued false or misleading statements and failed to disclose critical information to investors [2]. - Exelixis reported Q2 2025 financial results on July 28, 2025, indicating product revenue for cabozantinib was below expectations [2]. - The company decided not to proceed to the phase 3 portion of the STELLAR-305 study due to emerging competition and assessment of other commercial opportunities [2]. Group 2: Market Reaction - Following the announcement regarding the phase 3 trial decision, Exelixis shares fell by almost 16.8% the next day [2].

Core Viewpoint - A class action lawsuit has been filed against C3.ai, Inc. for alleged violations of securities laws, claiming the company made false and misleading statements regarding its revenue projections and the impact of its CEO's health on operations [1][4]. Group 1: Lawsuit Details - The lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - Investors who purchased C3's securities between February 26, 2025, and August 8, 2025, are encouraged to participate in the lawsuit [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against C3.ai - The complaint alleges that C3.ai made false and misleading statements that led investors to believe the company could reliably project its revenues and growth [4]. - The company downplayed the risks associated with the health concerns of CEO Thomas M. Siebel, which ultimately affected its optimistic projections for growth, earnings, and margins [4]. - When the truth about C3's operations and the impact of the CEO's health became known, investors suffered damages [4].

Core Viewpoint - The Schall Law Firm is investigating claims against CTO Realty Growth, Inc. for potential violations of securities laws, particularly regarding misleading statements about the sustainability of its dividend [1][2]. Group 1: Investigation Details - The investigation centers on whether CTO Realty Growth issued false or misleading statements and failed to disclose important information to investors [2]. - A report by Wolfpack Research, published on June 25, 2025, alleges that CTO misled investors about its dividend sustainability, leading to a share price decline of over 5.4% [2]. Group 2: Legal Representation - The Schall Law Firm offers free consultations for shareholders who believe they have suffered losses due to the alleged misleading information from CTO [3].

Group 1 - The Schall Law Firm is investigating claims on behalf of investors of Simulations Plus, Inc. for potential violations of securities laws [1] - The investigation centers on whether Simulations Plus issued false or misleading statements and failed to disclose relevant information to investors [2] - Following the Q3 2025 earnings report, Simulations Plus reported sales of $20.4 million, which was below the consensus estimate of $20.9 million, leading to a decline in the company's shares [2] Group 2 - The preliminary third-quarter sales figures released in June indicated lower expectations at $19 million to $20 million, compared to a consensus of $22.78 million [2]

Core Viewpoint - The Schall Law Firm is investigating Praxis Precision Medicines, Inc. for potential violations of securities laws related to misleading statements and undisclosed information affecting investors [1][2]. Group 1: Investigation Details - The investigation centers on whether Praxis issued false or misleading statements and failed to disclose critical information to investors [2]. - Praxis reported its Q2 2025 financial results on August 4, 2025, revealing concerning mid-state clinical results for its anti-seizure medication, vormatrigine [2]. - More than half of the patients in the trial experienced treatment-emergent adverse events, with nearly 25% of participants discontinuing the medication [2]. Group 2: Market Reaction - Following the announcement of the adverse clinical results, shares of Praxis fell by more than 5% on the same day [2].

Core Viewpoint - The Schall Law Firm is investigating Fortinet, Inc. for potential violations of securities laws, particularly regarding misleading statements and undisclosed information that may have affected investors [1][2]. Group 1: Investigation Details - The investigation centers on whether Fortinet issued false or misleading statements and failed to disclose critical information to investors [2]. - Fortinet's Q2 financial results, reported on August 6, 2025, have raised concerns among investors, particularly regarding the company's statement that 40% to 50% of its accelerated firewall refresh, estimated at $450 million and 650,000 units, was completed [2]. - Following the Q2 results and the confusion surrounding product revenue growth, Fortinet's shares dropped by 25.3% on August 7, 2025 [2].

Core Viewpoint - A class action lawsuit has been filed against Lineage, Inc. for alleged violations of federal securities laws related to misleading statements made during its IPO process [1][4]. Group 1: Lawsuit Details - The Schall Law Firm is representing investors who purchased Lineage's securities during its IPO in July 2024 and encourages them to contact the firm before September 30, 2025 [2]. - The lawsuit claims that Lineage made false and misleading statements that led to a weakening of demand as customers destocked excessive inventory and adjusted to changing consumer trends [4]. Group 2: Company Performance Issues - Lineage reportedly raised prices unsustainably prior to the IPO and failed to address demand problems through marketing or leveraging competitive advantages [4]. - The company's public statements are alleged to have been false and materially misleading throughout the class period, resulting in investor damages when the truth was revealed [4].

LOS ANGELES, July 31, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lockheed Martin Corporation ("Lockheed Martin" or "the Company") (NYSE: LMT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between January 23, 2024 and July 21, 2025, inclusive (the "Cla ...

Core Viewpoint - The Schall Law Firm is investigating Centene Corporation for potential violations of securities laws, particularly regarding misleading statements and undisclosed information that may have affected investors [1][2]. Group 1: Investigation Details - The investigation centers on whether Centene issued false or misleading statements and failed to disclose critical information to investors [2]. - A Seeking Alpha report indicated that Centene's shares declined after the company withdrew its 2025 earnings guidance, citing higher-than-expected costs related to Medicaid enrollees and underperformance in its Affordable Care Act plans [2]. - Following the announcement, Centene's shares fell by more than 39.5% during intraday trading on the same day [2]. Group 2: Company Background - Centene Corporation is involved in providing healthcare services, particularly through Medicaid and Affordable Care Act plans [2]. - The company reported a significant increase in medical cost trends in areas such as behavioral health, home health, and high-cost drugs [2].

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. for alleged violations of securities laws, specifically related to misleading statements made by the company during a defined class period [1][4]. Group 1: Lawsuit Details - The lawsuit pertains to investors who purchased Hims & Hers securities between April 29, 2025, and June 23, 2025 [2]. - Investors are encouraged to contact the Schall Law Firm before August 25, 2025, to discuss their rights and potential participation in the lawsuit [2][3]. Group 2: Allegations Against the Company - The complaint alleges that Hims & Hers made false and misleading statements regarding its marketing practices, particularly in relation to the promotion of products that could jeopardize patient safety [4]. - The company faced the risk of having its partnership with Novo Nordisk terminated due to these deceptive marketing activities [4]. - The misleading public statements resulted in financial damages to investors once the truth about the company's practices was revealed [4].